Table 2 Faecal concentrations of C. difficile toxins A and B stratified by therapy with vancomycin or fidaxomicin
Baseline | Mid-point | End-of-therapy | Follow-up | |
|---|---|---|---|---|
Toxin A | ||||
Fidaxomicin | 34.5 ± 39.4 (42.8 %); n = 3/7 | 0.7 ± 0.9 (14.3 %); n = 1/7 | 0.3 ± 0 (0 %); n = 0/6 | 0.3 ± 0 (0 %); n = 0/6 |
Vancomycin | 27.1 ± 31.5 (100 %); n = 5/5 | 0.3 ± 0 (0 %); n = 0/5 | 19.1 ± 26.6 (33.3 %); n = 1/3 | 35.5 ± 35.2 (50 %); n = 1/2 |
Toxin B | ||||
Fidaxomicin | 45.5 ± 27.9 (100 %); n = 7/7 | 4.5 ± 10.2 (14.3 %); n = 1/7 | 0.3 ± 0 (0 %); n = 0/6 | 5 ± 8.2 (33.3 %); n = 2/6 |
Vancomycin | 32.2 ± 39 (40 %); n = 2/5 | 3 ± 3.2 (60 %); n = 3/5 | 26.9 ± 37.5 (33.3 %); n = 1/3 | 25.3 ± 25 (50 %); n = 1/2 |